tbuckley/cabot-search huggingface dataset:
TMIC-58. THE CELLULAR AND MOLECULAR BASIS FOR MESENCHYMAL TRANSFORMATION IN GLIOMAS
Authors: Andrea Comba, Patrick J Dunn, Anna E Argento, Padma Kadiyala, Sebastien Motsch, Alon Kahana, Phillip E Kish, Maria Castro, Pedro Lowenstein
Journal: Neuro-Oncology (2019)

Abstract Mesenchymal gliomas are the most aggressive tumors that carry the worst prognosis. The origins of mesenchymal cells within brain tumors, remains poorly understood. They could originate either from invading mesenchymal cells, from perivascular smooth muscle actin+ cells, or from a mesenchymal transformation of tumor cells. Identifying the origin and function of mesenchymal cells within gliomas is essential as these cells contribute to increased glioma aggressiveness and tumor progression. In this study we used human biopsies and implantable and genetically engineered mouse models (GEMM) of GBM to study tumor mesenchymal transformation. GBM implantable models were used to analyze the molecular landscape by laser microdissection followed by RNA-Seq and bioinformatics analysis. Time lapse confocal imagining was implemented to analyze GBM cells dynamics. Our results indicate the existence of a complex intratumoral and peritumoral dynamic organization of glioma cells (i.e., Oncostreams). Multicellular structures of elongated cells compatible with mesenchymal differentiation. These structures play important roles in intratumoral movements, peritumoral invasion of normal brain, and overall glioma progression. We also show that oncostreams are molecularly distinct and display increased expression of mesenchymal genes such as Col1a1. Knocking down of Col1a1 in a GEMM of aggressive gliomas reduced tumor progression and significantly increased animal survival. Histological examination confirmed absence of Col1a1, and absence of morphologically identifiable oncostreams. Our results show that tumor cells, especially within oncostreams, display a fibroblastic-like morphology and express proteins typical of mesenchymal cells. The knockout of Col1a1 from tumoral cells eliminated oncostreams from tumors and delayed tumor progression. These data suggest that tumor cells expressing mesenchymal genes regulate the organization of mesenchymal multicellular structures, and determine glioma progression. We propose that inhibiting mesenchymal transformation of glioma cells will assist in the treatment of glioblastoma.
“Electronic Nose” Predicts Immunotherapy Response
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
β2-m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation
Authors: Daniel Hofbauer, Dimitrios Mougiakakos, Maike Büttner-Herold, Frank Neumann, Jens Nolting, Savita Bisht, Robert Zeiser, Shaima'A Hamarsheh, Stefano Ricagno, Mario Zaiss, Martin Eberhardt, Martin Boettcher, Katrin Bitterer, Andreas Mackensen, Heiko Bruns
Journal: Blood (2019)
N6-Methyladenosine RNA Methylation Regulators Contribute to Malignant Progression and Survival Prediction in Chronic Lymphocytic Leukemia
Authors: Ya Zhang, Xiaosheng Fang, Na Chen, Xiao Lv, Xueling Ge, Kang Lu, Xiangxiang Zhou, Juan Yang, Yang Han, Shunfeng Hu, Xin Wang
Journal: Blood (2019)
Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial
Authors: Franck Morschhauser, Carmelo Carlo-Stella, Fritz Offner, Gilles A. Salles, Martin Hutchings, Gloria Iacoboni, Anna Sureda, Michael Crump, Joaquin Martinez-Lopez, Denise Thomas, Peter N Morcos, Cristiano Ferlini, Abiraj Keelara, Ann-Marie E Bröske, Marina Bacac, Natalie Dimier, Tom Moore, Martin Weisser, Michael Dickinson
Journal: Blood (2019)
Palliative Care in the Nursing Home—Shifting Paradigms
Authors: Lauren J. Hunt, Caroline E. Stephens, Alexander K. Smith
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
KBTBD13 is an actin-binding protein that modulates muscle kinetics
Authors: Josine M. de Winter, Joery P. Molenaar, Michaela Yuen, Robbert van der Pijl, Shengyi Shen, Stefan Conijn, Martijn van de Locht, Menne Willigenburg, Sylvia J.P. Bogaards, Esmee S.B. van Kleef, Saskia Lassche, Malin Persson, Dilson E. Rassier, Tamar E. Sztal, Avnika A. Ruparelia, Viola Oorschot, Georg Ramm, Thomas E. Hall, Zherui Xiong, Christopher N. Johnson, Frank Li, Balazs Kiss, Noelia Lozano-Vidal, Reinier A. Boon, Manuela Marabita, Leonardo Nogara, Bert Blaauw, Richard J. Rodenburg, Benno Küsters, Jonne Doorduin, Alan H. Beggs, Henk Granzier, Ken Campbell, Weikang Ma, Thomas Irving, Edoardo Malfatti, Norma B. Romero, Robert J. Bryson-Richardson, Baziel G.M. van Engelen, Nicol C. Voermans, Coen A.C. Ottenheijm
Journal: Journal of Clinical Investigation (2019)

The mechanisms that modulate the kinetics of muscle relaxation are critically important for muscle function. A prime example of the impact of impaired relaxation kinetics is nemaline myopathy caused by mutations in KBTBD13 (NEM6). In addition to weakness, NEM6 patients have slow muscle relaxation, compromising contractility and daily life activities. The role of KBTBD13 in muscle is unknown, and the pathomechanism underlying NEM6 is undetermined. A combination of transcranial magnetic stimulation-induced muscle relaxation, muscle fiber- and sarcomere-contractility assays, low-angle x-ray diffraction, and superresolution microscopy revealed that the impaired muscle-relaxation kinetics in NEM6 patients are caused by structural changes in the thin filament, a sarcomeric microstructure. Using homology modeling and binding and contractility assays with recombinant KBTBD13, Kbtbd13-knockout and Kbtbd13R408C-knockin mouse models, and a GFP-labeled Kbtbd13-transgenic zebrafish model, we discovered that KBTBD13 binds to actin - a major constituent of the thin filament - and that mutations in KBTBD13 cause structural changes impairing muscle-relaxation kinetics. We propose that this actin-based impaired relaxation is central to NEM6 pathology.
EPID-18. NATIONAL TRENDS IN THE USE OF TARGETED AND IMMUNOTHERAPY IN THE UP FRONT MANAGEMENT OF GLIOBLASTOMA
Authors: Rodney Wegner, Richard White, Stephen Abel, Alexander Yu, Linda Xu, Stephen Karlovits, Tulika Ranjan
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Current standard of care for GBM involves an aggressive multimodality approach including surgical resection followed by adjuvant chemoradiation. Despite this approach, overall survival remains poor and treatment approaches continue to evolve. Given the successes of immunotherapy in other disease sites, implementation in GBM management may improve outcomes. METHODS We conducted this retrospective NCDB study to analyze treatment trends and outcomes from 2004–2015 regarding immunotherapy for GBM. We excluded patients treated without surgery, extracranial radiation, or chemotherapy as well as those lost to follow up. RESULTS Of the 39,317 eligible patients in this study, 511 were treated with immunotherapy and 38,806 lack thereof. Median overall survival for all patients was 15 months with a 2 and 5 year survival rate of 29% and 8%, respectively. Factors influencing delivery of immunotherapy included younger age, higher income, facility location in a metropolitan location, greater distance to the treatment facility, treatment at an academic facility, treatment outside of the years 2007 to 2009, and Caucasian race. On propensity matched analysis, survival was 18 months and 17 months with and without immunotherapy, respectively (p=0.15). Higher comorbidity, lower income, and male gender predicted for worse survival. CONCLUSIONS The results of this analysis show an initial decrease and then increase in the use of immunotherapy in the management of GBM. Propensity-matched analyses did not show an overall survival benefit.
Improving personalised therapy in metastatic breast cancer by implementing RNA sequencing based gene expression signatures
Authors: M. Schulze, M. Hlevnjak, V. Thewes, S. Elgaafary, A. Mavratzas, S. Fröhling, J. Seitz, M. Zapatka, P. Lichter, A. Schneeweiss
Journal: Annals of Oncology (2019)
Microrna-191 Regulates T-Cell Clonal Expansion during Graft-Versus-Host Disease
Authors: Chuanfeng Xiong, Wei Huang, Xiaoli Nie, Ying Huang, Yiqun Jiao, Yujing Zou, Charles Huang, Emilio Feijoo, Dong Pan, Diana M Cardona, Nelson J. Chao, Qi-jing Li, Benny J. Chen
Journal: Blood (2019)
Prognostic Value of Repeating Cardiac Magnetic Resonance in Patients With Acute Myocarditis
Authors: Giovanni Donato Aquaro, Yacob Ghebru Habtemicael, Giovanni Camastra, Lorenzo Monti, Santo Dellegrottaglie, Claudio Moro, Chiara Lanzillo, Alessandra Scatteia, Mauro Di Roma, Gianluca Pontone, Martina Perazzolo Marra, Andrea Barison, Gianluca Di Bella
Journal: Journal of the American College of Cardiology (2019)
Correction: The Kidney Failure Risk Equation for prediction of end stage renal disease in UK primary care: An external validation and clinical impact projection cohort study
Authors: Rupert W. Major, David Shepherd, James F. Medcalf, Gang Xu, Laura J. Gray, Nigel J. Brunskill
Journal: PLoS Medicine (2020)

[This corrects the article DOI: 10.1371/journal.pmed.1002955.].
New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia
Authors: Florence Pasquier, Caroline Marty, Frédérique Verdier, Sarah Grosjean, Claude Préhu, Stefan N. Constantinescu, Hana Raslova, Nicole Casadevall, William Vainchenker, Christine Bellanné-Chantelot, Isabelle Plo
Journal: Blood (2016)
CMET-39. DISPARITIES IN STEREOTACTIC RADIOSURGERY USE AND OUTCOMES FOR MELANOMA BRAIN METASTASES – AN AUSTRALIAN POPULATION-BASED STUDY
Authors: Wee Loon Ong, Morikatsu Wada, Farshad Foroudi
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION We aim to evaluate the use of stereotactic radiosurgery (SRS) among patients who received radiotherapy for melanoma brain metastases (MBM), and the associated outcomes. METHODS This is a population-based cohort of patients who received radiotherapy for MBM between 2013 and 2016, as captured in the Victorian Radiotherapy Minimum Dataset. Brain radiotherapy was classified as SRS (including multi-fraction stereotactic radiotherapy) and non-SRS. Mortality data was obtained through linkage with the Victorian Cancer Registry. The primary outcomes were: proportion of patients who had SRS for MBM, and overall survival (OS) following radiotherapy. Multivariate logistic regression was used to evaluate factors associated with SRS use, Kaplan Meier method for estimation of OS, and multivariate Cox regression for evaluation of factors associated with OS. RESULTS 294 patients received 551 courses of radiotherapy for MBM in this study, of which 39% (116/294) patients received SRS. Patients from higher socioeconomic status were more likely to have SRS – 49% in top quintile vs. 22% in lowest quintile (P&lt; 0.009). Patients treated in regional centres were less likely to have SRS compared to metropolitan centres (3% vs. 48%,P&lt; 0.001). In multivariate logistic regression, treatment in regional centres was the only factor independently associated with lower likelihood of receiving SRS (OR=0.04;95%CI=0.01–0.18;P&lt; 0.001). The median follow-up of the cohort was 3.8 months (range: 0.1–42 months). There were 227 death observed, with 12-month OS of 23%. There was significant difference in 12-month OS between patients who received SRS compared to those who did not receive SRS (43% vs. 11%; P&lt; 0.001). In multivariate Cox regression, the use of SRS was the only factor independently associated with OS (HR=0.38;95%CI=0.28–0.51;P&lt; 0.001). CONCLUSION We observed sociodemographic and institutional disparities in SRS use for MBM. The observed impact of SRS use on OS is most likely confounded by patient selections for SRS.
NUP98-HOXA9-Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML
Authors: Ivan Sloma, Philip Beer, Christophe Desterke, Elizabeth Bulaeva, Misha Bilenky, Michelle Moksa, Kamini Raghuram, Cedric Brimacombe, Karen Lambie, Ali G Turhan, Orianne Wagner-Ballon, Philippe Gaulard, R. Keith Humphries, Martin Hirst, Connie J. Eaves
Journal: Blood (2019)
Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias
Authors: James K McCloskey, Joelle Gagnon, Tara McCabe, Jocelyn Charlon, Shuqi Wang, Ruzong Fan, Stuart L. Goldberg, Jamie Koprivnikar
Journal: Blood (2019)
Stenosis Outcome at 1 and 3 Years after Transplantation Vs Standard-Care in Children with Sickle-Cell Anemia and Abnormal Transcranial Doppler with Stroke or No-Stroke History
Authors: Suzanne Verlhac, Catherine Paillard, Flaviu Gabor, Charlotte Jubert, Jean-Francois Chateil, Eleonore Petras, Valentine Brousse, Mariane De Montalembert, David Grévent, Isabelle Thuret, Lydia Divialle-Doumdo, Corinne Pondarré, Monique Elmaleh, Florence Missud, Corinne Guitton, Beatrice Husson, Cécile Arnaud, Annie Kamdem, Regis Peffault De Latour, Jean-Hugues Dalle, Benedicte Neven, Philippe Petit, Claire Galambrun, Francoise Bernaudin
Journal: Blood (2019)
GENE-06. INTEGRATIVE ANALYSIS OF DNA METHYLATION SUGGESTS DOWN-REGULATION OF ONCOGENIC PATHWAYS AND REDUCED SOMATIC MUTATION RATES IN SURVIVAL OUTLIERS OF GLIOBLASTOMA
Authors: Sojin Kim, Yun-Sik Dho
Journal: Neuro-Oncology (2019)

Abstract The study of survival outliers of glioblastoma (GBM) can provide important clues on gliomagenesis as well as on the ways to alter clinical course on this almost uniformly lethal cancer type. However, there has been little consensus on genetic and epigenetic signatures of the long-term survival outliers of GBM. In this study, we compared the two groups of survival outliers of glioblastoma with IDH wild-type, consisting of the GBM patients who lived longer than 3 years (n=17) and the patients who lived less than 1 year (n=12) in terms of genome-wide DNA methylation profile. Statistical analyses were performed to identify differentially methylated sites between the two groups. Functional implication of long-term survivors of GBM (LTS-GBM)-specific sites were investigated by comprehensive enrichment analyses with genomic and epigenomic features. We found that the genome of LTS-GBM is differentially methylated relative to short-term survivor patients depending on CpG density: hypermethylation near CpG islands (CGIs) and hypomethylation far from CGIs. Interestingly, these two patterns are associated with distinct oncogenic aspects in gliomagenesis. In the LTS-GBM-specific sites distant from CGI, somatic mutations of GBM are enriched with higher DNA methylation, suggesting that the hypomethylation in LTS-GBM can contribute to reduce the rate of somatic mutation. On the other hand, the hypermethylation near CGIs associates with transcriptional downregulation of genes involved in cancer progression pathways. Using independent cohorts of IDH1/2- wild type GBM, we also showed that these two patterns of DNA methylation can be used as molecular markers of LTS-GBM. Our results provide extended understanding of DNA methylation, especially of DNA hypomethylation, in cancer genome and reveal clinical importance of DNA methylation pattern as prognostic markers of GBM.
PRDM1 Binds an Extensive Network of Genes to Regulate Human Natural Killer Cell Homeostasis
Authors: Xuxiang Liu, Yunfei Shi, Yuping Li, Ru Chen, Sheng Pan, Gehong Dong, Qiang Gong, Javeed Iqbal, Haiqing Li, Jinhui Wang, Shuhua Yi, Timothy McKeithan, Wing C. Chan
Journal: Blood (2019)
&lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib
Authors: Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, Yuta Kobayashi, Kayoko Kasuya, Tomoya Sano, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Masaji Hashimoto, Hiromitsu Kumada
Journal: Liver Cancer (2019)

This study aimed to identify the utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) as a predictor of the response of hepatocellular carcinoma (HCC) to lenvatinib.We evaluated 28 consecutive patients with HCC diagnosed by dynamic CT or magnetic resonance imaging combined with 18F-FDG-PET/CT. The tumor-to-normal liver standardized uptake value ratio (TLR) of the target tumor was measured before treatment using 18F-FDG-PET/CT, with a TLR ≥2 classified as a high potential for malignant HCC. The treatment response was evaluated 2 weeks after the initiation of lenvatinib using modified Response Evaluation Criteria in Solid Tumors.Of the 28 patients, 12 (43%) presented with a TLR ≥2. Evaluation of the treatment response at 2 weeks in these 12 patients revealed that 2 (17%) exhibited a complete response, 8 (67%) a partial response, 2 (17%) stable disease, and none with progressive disease. Therefore, 10 of the 12 patients (83%) experienced an objective response to lenvatinib. On the other hand, 7 of the 16 patients with a TLR <2 (44%) experienced an objective response. Thus, the objective response rate was higher in patients with a TLR ≥2 than in those with a TLR <2. Multivariate logistic regression analysis revealed that a TLR ≥2 (odds ratio 10.53; p = 0.028) is a useful predictor of an early objective response at 2 weeks.Patients with unresectable HCC showed a good early treatment response to lenvatinib. High TLR (≥2) may be a useful predictor of an extremely rapid treatment response.
Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease
Authors: Jennifer S. Lees, Claire E. Welsh, Carlos A. Celis-Morales, Daniel Mackay, James Lewsey, Stuart R. Gray, Donald M. Lyall, John G. Cleland, Jason M. R. Gill, Pardeep S. Jhund, Jill Pell, Naveed Sattar, Paul Welsh, Patrick B. Mark
Journal: Nature Medicine (2019)
The Effect of Polyphenols in Olive Oil on Heart Disease Risk Factors
Authors: James B. Roufs
Journal: Annals of Internal Medicine (2007)

Letters6 March 2007The Effect of Polyphenols in Olive Oil on Heart Disease Risk FactorsJames B. Roufs, MS, RDJames B. Roufs, MS, RDFrom Intelligent Nutrition LLC, Long Beach, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-146-5-200703060-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: Are the polyphenol contents in Covas and colleagues' article (1) correct? It seems that the amount of polyphenol found in the 3 different olive oils is very low (0, 4, and 9 mg of polyphenols per 25 mL of olive oil, respectively)?Reference1. Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006;145:333-41. [PMID: 16954359] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Intelligent Nutrition LLC, Long Beach, California.Disclosures: Mr. Roufs has worked as a consultant in the dietary supplement industry. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Effect of Polyphenols in Olive Oil on Heart Disease Risk Factors María-Isabel Covas , Kristiina Nyyssönen , Henrik E. Poulsen , Jari Kaikkonen , Hans-Joachim F. Zunft , Holger Kiesewetter , Antonio Gaddi , Rafael de la Torre , Jaakko Mursu , Hans Bäumler , Simona Nascetti , Jukka T. Salonen , Montserrat Fitó , Jyrki Virtanen , Jaume Marrugat , and The Effect of Polyphenols in Olive Oil on Heart Disease Risk Factors María-Isabel Covas and Jukka T. Salonen The Effect of Polyphenols in Olive Oil on Heart Disease Risk Factors Luca Mascitelli , Francesca Pezzetta , and Jerome L. Sullivan Metrics 6 March 2007Volume 146, Issue 5Page: 394KeywordsCardiovascular therapyConflicts of interestMedical risk factorsOils ePublished: 6 March 2007 Issue Published: 6 March 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Factors Associated with Subsequent Cancers in Patients with Moderate or Severe Chronic Graft-Versus-Host Disease after Transplant for Hematologic Malignancy
Authors: Dana Schaar, Filip Pirsl, Seth M. Steinberg, Laura Parsons-Wandell, Michael Emanuel, Shaneil Flucker, Jeannette Nashed, Claire Ruben, Lauren M. Curtis, Edward W Cowen, Jacqueline Mays, Pashna N. Munshi, Annie Im, Ann Berger, Galen O Joe, Manuel B Datiles, Steven Z. Pavletic
Journal: Blood (2019)
Prognostic Value of Coronary CTA in Stable Chest Pain
Authors: Daniel O Bittner, Thomas Mayrhofer, Matt Budoff, Balint Szilveszter, Borek Foldyna, Travis R Hallett, Alexander Ivanov, Sumbal Janjua, Nandini M Meyersohn, Pedro V Staziaki, Stephan Achenbach, Maros Ferencik, Pamela S Douglas, Udo Hoffmann, Michael T Lu
Journal: JACC. Cardiovascular imaging (2019)
Chromatin Architecture Modulation in B-Cell Acute Lymphoblastic Leukemia Carrying DUX4 Fusions
Authors: Yosuke Tanaka, Masahito Kawazu, Satoshi Inoue, Shinya Kojima, Ueno Toshihide, Toshiaki Uno, Moe Tamura, Susumu Goyama, Toshio Kitamura, Shinichi Morishita, Hiroyuki Mano
Journal: Blood (2019)
HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation
Authors: Jenny M. Ho, Jessie J.F. Medeiros, Michelle Chan-Seng-Yue, Lauren Hummel, Andrea Arruda, Amanda Mitchell, Caroline J McNamara, James A Kennedy, Anne Tierens, Dawn Maze, Hubert Tsui, Mark D. Minden, Vikas Gupta, John E. Dick
Journal: Blood (2019)